InterveXion is a privately-held clinical-stage biopharmaceutical company developing novel products for the treatment of addiction disorders. Our lead clinical asset is IXT-m200, a monoclonal antibody directed against methamphetamine, which acts by re-partitioning methamphetamine away from its sites of action in the CNS. IXT-m200 has received US FDA Fast Track Designation, and is being studied in an ongoing Phase 2 proof-of-concept study (STAMPOUT; NCT03336866). We are also developing a novel vaccine (IXT-v100) against methamphetamine, which is in Preclinical Development.
Recent Posts
- InterveXion Therapeutics Awarded Federal Grant to Fund Ongoing Development Program for IXT-m200 for Methamphetamine Use Disorder
- Part 2: Immunotherapies—A New Tool To Treat Methamphetamine Addiction? | National Institute on Drug Abuse (NIDA)
- Part 1: Immunotherapies—A New Tool To Treat Methamphetamine Addiction? | National Institute on Drug Abuse (NIDA)
- As Deaths Rise, The Urgent Search For Medications To Treat Meth | CommonHealth
- A New Drug Scourge: Deaths Involving Meth Are Rising Fast – The New York Times
Archives
- May 2020
- February 2020
- January 2020
- December 2019
- November 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- February 2019
- January 2019
- December 2018
- November 2018
- May 2018
- January 2018
- October 2017
- June 2017
- January 2016
- January 2015
- November 2014
- February 2014
- August 2013
- July 2013
- December 2012
- November 2012
- May 2012
- April 2012
- July 2011
- April 2011
- October 2009
- September 2009
- March 2005
- January 2005
Recent Comments